VERU INC. Inventory Write-down
VERU INC. (VERU) reported Inventory Write-down of -$72.83 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2025-12-17
- VERU INC. inventory write-down for the quarter ending 2025-09-30 was -$72.83K, a 124.22% decline year-over-year.
- VERU INC. inventory write-down for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. inventory write-down for the quarter ending 2024-09-30 was $300.66K.
- VERU INC. inventory write-down for the quarter ending 2024-06-30 was $487.17K, a 14012.63% increase year-over-year.
- VERU INC. inventory write-down for fiscal 2025 was -$72.83K, a 104.65% decline from fiscal 2024.
- VERU INC. inventory write-down for fiscal 2024 was $1.57M, a 744.66% increase from fiscal 2023.
- VERU INC. inventory write-down for fiscal 2023 was $185.50K, a 126.17% increase from fiscal 2022.
- VERU INC. inventory write-down for fiscal 2022 was $82.02K, a 85.94% decline from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$72.83K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -$72.83K derived: sum of 2 quarters · filed 2025-12-17 | -$72.83K 10-K · filed 2025-12-17 | |
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | $300.66K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $787.83K derived: sum of 2 quarters · filed 2025-12-17 | $1.57M 10-K · filed 2025-12-17 | |
| 2024-06-30 | $487.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $1.27M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $779.00K 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | -$10.09K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | -$6.64K derived: sum of 2 quarters · filed 2024-12-16 | $185.50K 10-K · filed 2024-12-16 | |
| 2023-06-30 | $3.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | $195.59K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $192.13K 10-Q · filed 2024-05-08 | |||
| 2022-09-30 | $82.02K 10-K/A · filed 2024-04-01 | |||
| 2022-03-31 | $12.55K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | $408.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $540.99K derived: sum of 2 quarters · filed 2022-12-05 | $574.37K derived: sum of 3 quarters · filed 2022-12-05 | $583.50K 10-K · filed 2022-12-05 |
| 2021-06-30 | $132.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $165.95K derived: sum of 2 quarters · filed 2021-08-12 | $175.09K 10-Q · filed 2021-08-12 | $191.93K derived: sum of 4 quarters · filed 2021-12-02 |
| 2021-03-31 | $33.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | $42.51K 10-Q · filed 2021-05-12 | $59.35K derived: sum of 3 quarters · filed 2021-12-02 | $58.29K derived: sum of 4 quarters · filed 2021-12-02 |
| 2020-12-31 | $9.14K 10-Q · filed 2021-02-10 | $25.98K derived: sum of 2 quarters · filed 2021-12-02 | $24.91K derived: sum of 3 quarters · filed 2021-12-02 | $102.04K derived: sum of 4 quarters · filed 2021-12-02 |
| 2020-09-30 | $16.84K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $15.78K derived: sum of 2 quarters · filed 2021-12-02 | $92.90K derived: sum of 3 quarters · filed 2021-12-02 | $244.82K 10-K · filed 2021-12-02 |
| 2020-06-30 | -$1.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $76.06K derived: sum of 2 quarters · filed 2021-08-12 | $227.98K 10-Q · filed 2021-08-12 | $224.59K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $77.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | $229.05K 10-Q · filed 2021-05-12 | $225.66K derived: sum of 3 quarters · filed 2021-05-12 | $286.23K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $151.92K 10-Q · filed 2021-02-10 | $148.53K derived: sum of 2 quarters · filed 2021-02-10 | $209.10K derived: sum of 3 quarters · filed 2021-02-10 | $238.78K derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-09-30 | -$3.39K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $57.18K derived: sum of 2 quarters · filed 2020-12-10 | $86.86K derived: sum of 3 quarters · filed 2020-12-10 | $109.11K 10-K · filed 2020-12-10 |
| 2019-06-30 | $60.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-13 | $90.25K derived: sum of 2 quarters · filed 2020-08-13 | $112.50K 10-Q · filed 2020-08-13 | |
| 2019-03-31 | $29.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | $51.92K 10-Q · filed 2020-05-13 | ||
| 2018-12-31 | $22.25K 10-Q · filed 2020-02-12 | |||
| 2018-09-30 | $90.86K 10-K · filed 2019-12-12 | |||
| 2017-09-30 | $345.18K 10-K · filed 2018-12-13 | |||
| 2016-09-30 | -$8.63K 10-K · filed 2018-01-02 | |||
| 2015-09-30 | $173.63K 10-K · filed 2018-01-02 | |||
| 2014-09-30 | $37.60K 10-K · filed 2016-12-12 | |||
| 2013-09-30 | -$6.66K 10-K · filed 2015-12-02 | |||
| 2012-09-30 | $128.36K 10-K · filed 2014-12-02 | |||
| 2011-09-30 | $177.73K 10-K · filed 2013-12-03 | |||
| 2010-09-30 | -$2.07K 10-K · filed 2012-12-04 | |||
| 2009-09-30 | $68.90K 10-K · filed 2011-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |